CY1108680T1 - Σχετιζομενα με ογκους πεπτιδια δεσμευμενα σε μορια mhc - Google Patents

Σχετιζομενα με ογκους πεπτιδια δεσμευμενα σε μορια mhc

Info

Publication number
CY1108680T1
CY1108680T1 CY20081101508T CY081101508T CY1108680T1 CY 1108680 T1 CY1108680 T1 CY 1108680T1 CY 20081101508 T CY20081101508 T CY 20081101508T CY 081101508 T CY081101508 T CY 081101508T CY 1108680 T1 CY1108680 T1 CY 1108680T1
Authority
CY
Cyprus
Prior art keywords
relates
mhc molecules
peptides
nos
volume made
Prior art date
Application number
CY20081101508T
Other languages
English (en)
Inventor
Toni Weinschenk
Hans-Georg Rammensee
Stefan Stevanovic
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of CY1108680T1 publication Critical patent/CY1108680T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464448—Regulators of development
    • A61K39/46445—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464452—Transcription factors, e.g. SOX or c-MYC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)

Abstract

Η εφεύρεση αφορά ένα σχετιζόμενο με όγκους πεπτίδιο με μία αμινοξική αλληλουχία που επιλέχθηκε από την ομάδα αποτελούμενη από αλληλ. με τον αναγνωριστικό αριθμ. 1 έως αναγνωριστικό αριθμ. 79 από το συνημμένο πρωτόκολλο αλληλουχίας, όπου το πεπτίδιο παρουσιάζει την ικανότητα να δεσμεύει ένα μόριο του ανθρώπινου μείζονος συμπλέγματος ιστοσυμβατότητας (MHC) κλάσης I. Η εφεύρεση αφορά περαιτέρω την χρήση των πεπτιδίων για την παρασκευή ενός φαρμάκου και για την θεραπεία των καρκινικών νόσων. Επίσης περιγράφεται μία φαρμακευτική σύνθεση, η οποία παρουσιάζει τουλάχιστον ένα από τα πεπτίδια.
CY20081101508T 2002-05-29 2008-12-30 Σχετιζομενα με ογκους πεπτιδια δεσμευμενα σε μορια mhc CY1108680T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10225144A DE10225144A1 (de) 2002-05-29 2002-05-29 An MHC-Moleküle bindende Tumor-assoziierte Peptide
EP06015805A EP1734048B1 (de) 2002-05-29 2003-03-27 An MHC-Moleküle bindende Tumor-assoziierte Peptide

Publications (1)

Publication Number Publication Date
CY1108680T1 true CY1108680T1 (el) 2014-04-09

Family

ID=29557592

Family Applications (5)

Application Number Title Priority Date Filing Date
CY20081101297T CY1108507T1 (el) 2002-05-29 2008-11-13 Σχετιζομενα με ογκους πεπτιδια δεσμευμενα σε μορια mhc
CY20081101425T CY1108673T1 (el) 2002-05-29 2008-12-09 Σχετιζομενα με ογκους πεπτιδια δεσμευμενα σε μορια mhc
CY20081101508T CY1108680T1 (el) 2002-05-29 2008-12-30 Σχετιζομενα με ογκους πεπτιδια δεσμευμενα σε μορια mhc
CY20101100714T CY1110723T1 (el) 2002-05-29 2010-07-30 Σχετιζομενα με ογκους πεπτιδια δεσμευμενα σε μορια mhc
CY20101100991T CY1111174T1 (el) 2002-05-29 2010-11-03 Σχετιζομενα με ογκους πεπτιδια δεσμευμενα σε μορια mhc

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CY20081101297T CY1108507T1 (el) 2002-05-29 2008-11-13 Σχετιζομενα με ογκους πεπτιδια δεσμευμενα σε μορια mhc
CY20081101425T CY1108673T1 (el) 2002-05-29 2008-12-09 Σχετιζομενα με ογκους πεπτιδια δεσμευμενα σε μορια mhc

Family Applications After (2)

Application Number Title Priority Date Filing Date
CY20101100714T CY1110723T1 (el) 2002-05-29 2010-07-30 Σχετιζομενα με ογκους πεπτιδια δεσμευμενα σε μορια mhc
CY20101100991T CY1111174T1 (el) 2002-05-29 2010-11-03 Σχετιζομενα με ογκους πεπτιδια δεσμευμενα σε μορια mhc

Country Status (15)

Country Link
US (5) US7396904B2 (el)
EP (5) EP1734049B1 (el)
JP (5) JP4472520B2 (el)
AT (5) ATE478088T1 (el)
AU (2) AU2003224001B2 (el)
CA (5) CA2736926C (el)
CY (5) CY1108507T1 (el)
DE (6) DE10225144A1 (el)
DK (5) DK2006294T3 (el)
ES (5) ES2317378T3 (el)
HR (1) HRP20041108B1 (el)
PL (5) PL211158B1 (el)
PT (5) PT1734049E (el)
SI (5) SI2006294T1 (el)
WO (1) WO2003102023A1 (el)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7892559B2 (en) * 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
DE10225139A1 (de) * 2002-05-29 2004-02-26 Immatics Biotechnologies Gmbh Verfahren zur Identifizierung von immunreaktiven Peptiden
US20050221350A1 (en) 2002-05-29 2005-10-06 Toni Weinschenk Method for identifying immunoreactive peptides
US7670604B2 (en) 2002-12-13 2010-03-02 Aurelium Biopharma, Inc. Vimentin directed diagnostics and therapeutics for multidrug resistant neoplastic disease
ES2661082T3 (es) * 2003-01-30 2018-03-27 Survac Aps Péptidos derivados de survivina y uso de los mismos
DE10313819A1 (de) * 2003-03-24 2004-10-07 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
NZ548166A (en) * 2003-12-01 2010-06-25 Meiji Dairies Corp Peptide inhibiting angiontensin converting enzyme
EP1695089A1 (en) * 2003-12-15 2006-08-30 Aurelium Biopharma Inc. Vimentin directed diagnostics and therapeutics for multidrug resistant neoplastic disease
DE102004011503A1 (de) * 2004-01-28 2005-09-15 Immatics Biotechnologies Gmbh Verfahren zur Identifizierung und Quantifizierung von tumor-assoziierten Peptiden
DE102004026135A1 (de) * 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
ATE421533T1 (de) * 2004-10-02 2009-02-15 Immatics Biotechnologies Gmbh Immunogene t-helfer epitope von menschlichen tumorantigenen und deren verwendung in immunotherapeutischen methoden
IL172896A0 (en) * 2005-12-29 2006-06-11 Yeda Res & Dev Cxcr4 inhibition
US20090004213A1 (en) * 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
KR101351195B1 (ko) 2007-07-27 2014-01-14 이매틱스 바이오테크놀로지스 게엠베하 면역 치료를 위한 새로운 면역원성 에피톱
WO2009129498A2 (en) * 2008-04-17 2009-10-22 Immuneregen Biosciences, Inc. Substance p and analogs thereof as a cancer immunogenic composition adjuvant
DK2119726T5 (en) 2008-05-14 2018-03-26 Immatics Biotechnologies Gmbh Novel and powerful MHC class II peptides derived from survivin and neurocan
CN101451975B (zh) * 2008-12-29 2012-01-25 浙江大学 一种检测胃癌预后与分期血清蛋白质的方法
US8075895B2 (en) * 2009-09-22 2011-12-13 Janssen Pharmaceutica N.V. Identification of antigenic peptides from multiple myeloma cells
GB201004575D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
GB201009222D0 (en) * 2010-06-02 2010-07-21 Immatics Biotechnologies Gmbh Improved cancer therapy based on tumour associated antigens derived from cyclin D1
US9555074B2 (en) 2010-10-08 2017-01-31 Regents Of The University Of Minnesota Annexin II compositions
MY191939A (en) 2013-08-05 2022-07-19 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors, such as lung cancer, including nsclc
JPWO2015050259A1 (ja) * 2013-10-03 2017-03-09 大日本住友製薬株式会社 腫瘍抗原ペプチド
EP3068428B1 (en) 2013-11-13 2022-08-17 Regents of the University of Minnesota Annexin ii variant compositions and methods
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
PT3388075T (pt) 2015-03-27 2023-08-18 Immatics Biotechnologies Gmbh Novos péptidos e combinações de péptidos para uso em imunoterapia contra vários tumores
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
MA42294B1 (fr) 2015-07-01 2020-11-30 Immatics Biotechnologies Gmbh Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers
GB201520558D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520568D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd Peptides
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201521746D0 (en) * 2015-12-10 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
SG10202111399YA (en) 2015-12-22 2021-11-29 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
DE102016005550A1 (de) 2016-05-09 2017-11-09 Emc Microcollections Gmbh Adjuvans zur lnduzierung einer zellulären lmmunantwort
JP7075125B2 (ja) 2016-05-25 2022-05-25 イマティクス バイオテクノロジーズ ゲーエムベーハー 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ
GB201609193D0 (en) 2016-05-25 2016-07-06 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
EP4317432A3 (en) 2016-12-08 2024-04-17 Immatics Biotechnologies GmbH T cell receptors with improved pairing
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
KR102184377B1 (ko) 2018-02-19 2020-11-30 고려대학교 산학협력단 열충격단백질의 에피토프를 포함하는 백신 및 이의 용도
WO2019160383A1 (ko) * 2018-02-19 2019-08-22 고려대학교 산학협력단 열충격단백질의 에피토프를 포함하는 백신 및 이의 용도
BR102018010523A2 (pt) * 2018-05-23 2020-04-28 Univ Estadual Campinas Unicamp peptídeo, composição farmacêutica compreendendo o mesmo e uso

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810781A (en) * 1987-01-15 1989-03-07 The George Washington University Methods of preparing epitopes of tumor associated antigens
US5739009A (en) * 1996-12-12 1998-04-14 Incyte Pharmaceuticals, Inc. Adipocyte-specific differentiation-related protein
US6977074B2 (en) * 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
DE19837015C2 (de) * 1998-08-14 2003-03-20 Vasopharm Biotech Gmbh Isolierte und gereinigte humane lösliche Guanylylcyclase alpha1/beta1 (hsGCalpha1/beta1)
US6809179B1 (en) 1999-08-04 2004-10-26 Boehringer Ingelheim International Gmbh Tumor-associated antigen (R11)
DE19936563A1 (de) 1999-08-04 2001-02-08 Boehringer Ingelheim Int Tumorassoziiertes Antigen
WO2001063294A2 (en) * 2000-02-24 2001-08-30 Oxford Glycosciences (Uk) Limited Diagnosis of bipolar affective disorder (bad) and unipolar depression
WO2002050103A2 (en) * 2000-12-20 2002-06-27 Glaxosmithkline Biologicals S.A. Tumour-related antigens
US20030170719A1 (en) * 2000-12-28 2003-09-11 Akio Matsuda NF-kappa B activating gene
WO2002086443A2 (en) * 2001-04-18 2002-10-31 Protein Design Labs, Inc Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
US6867283B2 (en) * 2001-05-16 2005-03-15 Technion Research & Development Foundation Ltd. Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells
WO2002101075A2 (en) * 2001-06-13 2002-12-19 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
WO2003048323A2 (en) * 2001-12-03 2003-06-12 Bristol-Myers Squibb Company Polynucleotides and polypeptides associated with the development of rheumatoid arthritis

Also Published As

Publication number Publication date
HRP20041108A2 (en) 2005-10-31
CA2736974A1 (en) 2003-12-11
CA2736972C (en) 2014-08-05
JP5042300B2 (ja) 2012-10-03
EP1507795B1 (de) 2008-10-08
JP5042303B2 (ja) 2012-10-03
EP1734048B1 (de) 2008-12-17
ATE466872T1 (de) 2010-05-15
CY1108673T1 (el) 2014-04-09
CA2736926A1 (en) 2003-12-11
EP2014673B1 (de) 2010-05-05
DE50310882D1 (de) 2009-01-15
CY1111174T1 (el) 2015-06-11
ATE478088T1 (de) 2010-09-15
ES2350461T3 (es) 2011-01-24
ATE410442T1 (de) 2008-10-15
SI1507795T1 (sl) 2009-04-30
CA2736972A1 (en) 2003-12-11
JP2010099080A (ja) 2010-05-06
ATE416188T1 (de) 2008-12-15
CA2736921C (en) 2013-09-03
AU2010200689B2 (en) 2012-07-12
WO2003102023A1 (de) 2003-12-11
EP2014673A1 (de) 2009-01-14
DE50312701D1 (de) 2010-06-17
JP2010099079A (ja) 2010-05-06
HRP20041108B1 (hr) 2013-11-08
ATE417859T1 (de) 2009-01-15
ES2317379T3 (es) 2009-04-16
DE50310613D1 (de) 2008-11-20
EP1734049B1 (de) 2008-12-03
DK1507795T3 (da) 2008-12-08
JP2010099078A (ja) 2010-05-06
PT2014673E (pt) 2010-08-04
JP2006511196A (ja) 2006-04-06
CA2487137C (en) 2013-02-19
AU2003224001A1 (en) 2003-12-19
US20100184211A1 (en) 2010-07-22
US8399613B2 (en) 2013-03-19
US7666984B2 (en) 2010-02-23
AU2003224001B2 (en) 2010-03-11
CY1110723T1 (el) 2015-06-10
EP1507795A1 (de) 2005-02-23
SI2006294T1 (sl) 2010-11-30
DE50310952D1 (de) 2009-01-29
PT1507795E (pt) 2008-12-26
EP2006294A1 (de) 2008-12-24
PL206306B1 (pl) 2010-07-30
PT1734048E (pt) 2009-01-02
PL210356B1 (pl) 2012-01-31
EP1734048A1 (de) 2006-12-20
ES2314196T3 (es) 2009-03-16
ES2317378T3 (es) 2009-04-16
US20100183644A1 (en) 2010-07-22
DK1734049T3 (da) 2009-01-19
PL211159B1 (pl) 2012-04-30
PL211158B1 (pl) 2012-04-30
PL373700A1 (en) 2005-09-05
US20080051347A1 (en) 2008-02-28
CA2487137A1 (en) 2003-12-11
JP5042301B2 (ja) 2012-10-03
AU2010200689A1 (en) 2010-03-18
EP1734049A1 (de) 2006-12-20
CA2736921A1 (en) 2003-12-11
DK1734048T3 (da) 2009-02-23
US20050222390A1 (en) 2005-10-06
PT1734049E (pt) 2008-12-26
JP5042302B2 (ja) 2012-10-03
US7396904B2 (en) 2008-07-08
JP4472520B2 (ja) 2010-06-02
PT2006294E (pt) 2010-11-12
CY1108507T1 (el) 2014-04-09
DK2006294T3 (da) 2010-12-13
EP2006294B1 (de) 2010-08-18
DE10225144A1 (de) 2003-12-18
PL211157B1 (pl) 2012-04-30
DE50313004D1 (de) 2010-09-30
ES2348468T3 (es) 2010-12-07
US8536304B2 (en) 2013-09-17
JP2010088449A (ja) 2010-04-22
US20080057077A1 (en) 2008-03-06
CA2736926C (en) 2015-11-17
US7763711B2 (en) 2010-07-27
SI2014673T1 (sl) 2010-09-30
SI1734049T1 (sl) 2009-02-28
SI1734048T1 (sl) 2009-02-28
DK2014673T3 (da) 2010-08-30
CA2736974C (en) 2014-09-02

Similar Documents

Publication Publication Date Title
CY1108680T1 (el) Σχετιζομενα με ογκους πεπτιδια δεσμευμενα σε μορια mhc
WO2005116051A3 (de) An mhc-moleküle bindende tumor-assoziierte peptide
CY1118037T1 (el) Αντισωματα εναντι του αβητα και h χρηση τους
CY1117387T1 (el) ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ
CY1107881T1 (el) Τροποποιημενα πεπτιδια ως θεραπευτικοι παραγοντες
CY1109786T1 (el) Μεθοδοι για την θεραπευτικη αγωγη ρευματικων ασθενειων με την χρησιμοποιηση ενος διαλυτου μοριου ctla4
CY1110634T1 (el) Μεθοδοι προληψης και θεραπειας της νοσου του αλτσχαϊμερ (ad)
CY1106662T1 (el) Αντι-igf-ir αντισωματα και οι εφαρμογες τους
CY1117065T1 (el) Υβριδικη και διαδοχικη εκφραση νεϊσσεριακα λαμβανομενων πρωτεϊνων
CY1114643T1 (el) Νεοπλασματικες κυτταρικες σειρες nm-f9 (dsm acc2606) και nm-d4 (dsm acc2605), χρησεις αυτων
CY1111283T1 (el) Μορια με παρατεταμενες ημι-περιοδους ζωης, συνθεσεις και χρησεις εξ αυτων
EA200901129A1 (ru) Нуклеиновые кислоты и полипептиды нового рецептора
HUP0201737A2 (hu) Anti-CTLA-4 antitestek alkalmazása
CY1106236T1 (el) Μεθοδοι και συνθεσεις για παραταση ημιπepιοδων αποβολης βιοδραστικων ενωσεων
CY1110530T1 (el) Ανοσοσφαιρινες που εξουδετερωνουν το nogoa για τη θεραπεια νευρολογικων ασθενειων
CY1109045T1 (el) Ρετινοειδη για τη θεραπεια του εμφυσηματος
EA200501206A1 (ru) Производные от сурвивина пептиды и их применение
CY1111079T1 (el) Πεπτιδιο
HUP0202512A2 (hu) Fehérjék polimerizációját gátló anyagok és eljárások ezek alkalmazására
CY1105380T1 (el) Προτιμωμενα τμηματα της νευρικης νηματικης πρωτεϊνης και μεθοδοι χρησης αυτων
CY1109843T1 (el) Αναλογα της βιταμινης d
BR9809914A (pt) Genes de moracella receptores de lactoferrina
CY1108570T1 (el) Gd3-μιμητικα πεπτιδια
DE69931482D1 (de) Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
DE69636285D1 (de) ISOLIERTES FrpB NUKLEINSÄUREMOLEKÜL UND ENTSPRECHENDE IMPFSTOFF